Petition To Restrict St. John’s Wort Draws Fire From Industry
This article was originally published in The Tan Sheet
Executive Summary
Industry trade groups argue the Pharmacists Planning Service’s petition filed Jan. 9 to move St. John’s wort products behind the counter is “not a very viable petition,” but are concerned about its potential implications. Regulatory authority to put a supplement BTC appears to be outside FDA’s powers.
You may also be interested in...
In Brief
NAD refers Solace to FTC; ERSP chastises TriVita for testimonials; Perrigo gains second China formula distributor; CHPA comments on lobbying regulations; Acetaminophen linked to asthma in children; CSPI pushes for St. John’s wort warning
St. John’s Wort “Significantly More Effective” Than Prozac, Study Finds
St. John's wort is more effective at treating major depressive disorder (MDD) than fluoxetine (Eli Lilly's Prozac), according to a study published in the October Journal of Clinical Psychopharmacology.
Ephedra Safety Taken Up By House Commerce Cmte, Cytodyne Sent Letter
The House Energy & Commerce Committee launched an investigation into the safety of ephedra Feb. 28 by sending letters to FDA Commissioner Mark McClellan, MD/PhD, and Cytodyne Technologies President Robert Chinery